Pharmaceuticals, Biotechnology and Life Sciences
Sandoz Tuesday said it got approval from US Food and Drug Administration for its biosimilar Ziextenzo, which is in particularly significant since Sandoz short-acting filgrastim Zarxio is the first biosimilar to surpass its reference biologic in US market share.
4D pharma Wednesday said that its clinical study with Merck to test MRx0518 combined with Keytruda further support its continued investment into our oncology franchise.
Biogen and Alkermes got approval from USFDA for Vumertiy, a novel oral fumarate with a distinct chemical structure, for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.
Amgen said in a press release Tuesday it’s total revenues decreased 3% to $5.7 billion compared with the same period last year, reflecting the impact of biosimilar and generic competition against key products.
Q-linea AB has received the official response including a number of clarifications and very positive feedback from the US Food and Drug Administration, FDA, regarding the company’s planned pivotal clinical trial with ASTar in the United States.
NEW YORK–(BUSINESS WIRE)–$BMY–Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol-Myers Squibb”) announced today the extension of the expiration date of the offers to…
Serial entrepreneur and computer scientist Bryan Brandenburg advances biomedical and life extension simulation and visualization AI technologies at the helm…
RALEIGH, N.C.–(BUSINESS WIRE)–Arrevus Inc. (www.arrevus.com), a biotechnology company developing novel therapeutics for patients with unmet medical needs, today announced the…
Dendreon has completed enrollment of of 450 patients, in Phase 3 ProVent clinical trial testing Sipuleucel-T in men on active…
Providing new patient treatment options, accelerating development of life-changing medicines